Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie’s disease in the outpatient setting: a pilot study

International Journal of Impotence Research volume 36, pages 140–145 (2024)Cite this article

Subjects

Abstract

The objective of this study is to evaluate the safety and feasibility of the combined simultaneous percutaneous needle tunneling coupled with injection of platelet-rich plasma in the outpatient department for the treatment of Peyronie’s disease. This prospective, non-randomized, cohort and preliminary study included patients who underwent this procedure from November 2020 to July 2022. The main outcome was an improvement in penile curvature. Fifty-four patients were enrolled and underwent 6 sessions under local anesthesia followed by vacuum therapy for the treatment of Peyronie’s disease in our outpatient unit. The amendment of the curvature angle was significant with a median correction percentage of −44.40% interquartile range (−66.70 to (−39.70)), [p-value = 0.001, 95% CI (−29.76 to (−18.02)), paired Student’s t-test]. The median pre-treatment curvature angle was 45° (40–75), and the median post-treatment was 30° (20–40). The median score for pain during the procedure was 3 (0–4.25) according to a 10-point visual analogic scale. After two hours, 20.37% of patients still had pain but none required any pain medication. 50% of patients had a minor hematoma and 75.93% patients reported penile ecchymosis. A single patient reported an injection site skin infection. In our experience percutaneous needle tunneling with platelet-rich plasma injections for Peyronie’s disease in the outpatient setting is a safe, effective, and feasible treatment of penile deformity for PD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Artwork that simplifies the process and production of Platelet-Rich Plasma (PRP).
Fig. 2: Artwork of percutaneous needle tunneling technique.

Similar content being viewed by others

Data availability

The data that supports the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.

References

  1. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21:347–54.

    Article  CAS  PubMed  Google Scholar 

  2. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–8.

    Article  PubMed  Google Scholar 

  3. Gonzalez‐Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009;6:353–62.

    Article  PubMed  Google Scholar 

  4. Gelbard MK, Dorey F, James K. The natural History of Peyronie’s disease. J Urol. 1990;144:1376–9.

    Article  CAS  PubMed  Google Scholar 

  5. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur Urol. 2001;40:525–30.

    Article  PubMed  Google Scholar 

  6. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–3.

    Article  PubMed  Google Scholar 

  7. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The Incidence of Peyronie’s Disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146:1007–9.

    Article  CAS  PubMed  Google Scholar 

  8. Culha MG, Erkan E, Cay T, Yücetaş U. The effect of platelet-rich plasma on Peyronie’s disease in rat model. Urol Int. 2019;102:218–23.

    Article  PubMed  Google Scholar 

  9. Levine LA, Larsen SM. Surgery for Peyronie’s disease. Asian J Androl. 2013;15:27. ncbi.nlm.nih.gov/pmc/articles/PMC3739133/.

  10. Rod X, Akakpo W, Roupret M. Efficacité et tolérance des traitements locaux en injections pour le traitement de la maladie de La Peyronie : revue de la littérature. Progs Urol. 2021;31:1072–9.

    Article  CAS  Google Scholar 

  11. Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie’s Disease (PD). Int J Impot Res. 2018;30:171–8.

    Article  PubMed  Google Scholar 

  12. Terrier JE, Nelson CJ. Psychological aspects of Peyronie’s disease. Transl Androl Urol. 2016;5:290–5.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977–84.

    Article  PubMed  Google Scholar 

  14. Alkandari MH, Touma N, Carrier S. Platelet-rich plasma injections for erectile dysfunction and peyronie’s disease: a systematic review of evidence. Sex Med Rev. 2022;10:341–52.

    Article  PubMed  Google Scholar 

  15. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13:905–23. https://pubmed.ncbi.nlm.nih.gov/27215686/.

    Article  PubMed  Google Scholar 

  16. Chong W, Tan RBW. Injectable therapy for Peyronie’s disease. Transl Androl Urol. 2016;5:310–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Levine LA, Costabile RA. Is intralesional verapamil effective therapy for Peyronie’s disease? J Urol. 2012 ;188:704–6.

    Article  PubMed  Google Scholar 

  18. Milam DF. Intralesional interferon-α2b improves penile curvature in Peyronie’s disease. J Urol. 2015;194:1533.

    Article  PubMed  Google Scholar 

  19. Zucchi A, Costantini E, Cai T, Cavallini G, Liguori G, Favilla V, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4:e85–90.

    Article  PubMed Central  Google Scholar 

  20. Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open‐label study. J Sex Med. 2015;12:248–58.

    Article  PubMed  Google Scholar 

  21. Mohit K. H-22411: BOTOX® for Peyronie’s disease. 2020. https://clinicaltrials.gov/ct2/show/NCT00812838.

  22. Carson CC, Sadeghi-Nejad H, Tursi JP, Smith TM, Kaufman GJ, Gilbert K, et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116:815–22. https://pubmed.ncbi.nlm.nih.gov/25818264/.

  23. Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176:394–8. https://pubmed.ncbi.nlm.nih.gov/16753449/.

    Article  CAS  PubMed  Google Scholar 

  24. Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifylline. Glob J Health Sci. 2014;6:23–30. https://pubmed.ncbi.nlm.nih.gov/25363175/.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62:543–52. https://pubmed.ncbi.nlm.nih.gov/22658761/.

    Article  PubMed  Google Scholar 

  26. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s Disease: AUA Guideline. J Urol. 2015;194:745–53. https://pubmed.ncbi.nlm.nih.gov/26066402/.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197–209. https://pubmed.ncbi.nlm.nih.gov/29792593/.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie’s disease. Int J Impot Res. 2012;24:1–10. https://www.nature.com/articles/ijir201145.

    Article  CAS  PubMed  Google Scholar 

  29. Virag R, Sussman H, Lambion S, de Fourmestraux V. Evaluation of the benefit of using a combination of autologous platelet rich-plasma and hyaluronic acid for the treatment of Peyronie’s disease. Sex Health Issues. 2017;1:1–8.

  30. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835–70.

    Article  CAS  PubMed  Google Scholar 

  31. Galliera E, Corsi MM, Banfi G. Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. J Biol Regul Homeost Agents. 2012;26:35S–42S.

    CAS  PubMed  Google Scholar 

  32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement. Epidemiology. 2007;18:800–4.

    Article  Google Scholar 

  33. DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthrosc: J Arthrosc Relat Surg. 2012;28:998–1009.

    Article  Google Scholar 

  34. Fernández-Pascual E, González-García FJ, Angulo J, Cerezo E, Quintana LM, Turo J, et al. Optimizing collagenase Clostridium histolyticum therapy for Peyronie’s disease using a novel approach with percutaneous needle tunnelling. BJU Int. 2019;124:1055–62.

    Article  PubMed  Google Scholar 

  35. Fernández-Pascual E, González-García FJ, García-Criado E, Souto AD, Marcos D, Angulo J, et al. V04-07 How to improve your xiapex results in Peyronie’s disease: the percutaneous needle tunnelling (PNT) technique. step-by-step surgical video. J Urol. 2019;201.

  36. Ferretti L, Madec FX, Akakpo W, Methorst C, Carnicelli D, Terrier JE, et al. Recommandations pour l’évaluation et la prise en charge de la maladie de Lapeyronie : rapport du comité d’andrologie et de médecine sexuelle de l’AFU. Prog Urol. 2021;31:477–94.

    Article  CAS  PubMed  Google Scholar 

  37. Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  PubMed  Google Scholar 

  38. Egui Rojo MA, Moncada Iribarren I, Carballido Rodriguez J, Martinez-Salamanca JI. Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects. Ther Adv Urol. 2014;6:192–7.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120:717–23.

    Article  CAS  PubMed  Google Scholar 

  40. Fernández Pascual E, Carballo N, Cerezo E, Fraile A, Martínez Ballesteros C, Peinado F, et al. HP-09-003 Clinical outcomes of the use of Collagenase Clostridium Histolyticum (CCH) for peyronie’s disease (PD). J Sex Med. 2017;14:e160–1.

    Article  Google Scholar 

  41. Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202:599–610.

    Article  PubMed  Google Scholar 

  42. Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int. 2019;123:694–702.

    Article  PubMed  Google Scholar 

  43. Martínez‐Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, del Portillo L, et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11:506–15.

    Article  PubMed  Google Scholar 

  44. Ibrahim A, Gazzard L, Alharbi M, Rompré-Brodeur A, Aube M, Carrier S. Evaluation of oral pentoxifylline, colchicine, and penile traction for the management of Peyronie’s Disease. Sex Med. 2019;7:459–63.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106:1178–80.

    Article  PubMed  Google Scholar 

  46. Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie’s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017;14:1430–7.

    Article  PubMed  Google Scholar 

  47. Khouaja K, Delmas V, Boccon-Gibod L. [Leriche technique for the treatment of La Peyronie’s disease]. Prog Urol. 2004;14:586–9.

    PubMed  Google Scholar 

  48. Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59:61.

    Article  PubMed  Google Scholar 

  49. Anitua E, Andia I, Ardanza B, Nurden P, Nurden A. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15.

    Article  CAS  PubMed  Google Scholar 

  50. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop Relat Res. 1998;355S:S7–21.

    Article  Google Scholar 

  51. Eppley BL, Woodell JE, Higgins J. Platelet Quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114:1502–8.

  52. Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg. 2005;16:1043–54.

    Article  PubMed  Google Scholar 

  53. Woodall J, Tucci M, Mishra A, Asfour A, Benghuzzi H. Cellular effects of platelet rich plasmainterleukin1 release from prp treated macrophages. Biomed Sci Instrum. 2008;44:489–94.

    PubMed  Google Scholar 

  54. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013;9:721–30.

    Article  CAS  PubMed  Google Scholar 

  55. Randelli P, Randelli F, Ragone V, Menon A, D’Ambrosi R, Cucchi D, et al. Regenerative medicine in rotator cuff injuries. Biomed Res Int. 2014;2014:1–9.

    Article  Google Scholar 

  56. Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014;16:204.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Weiss RA. Autologous cell therapy. Facial Plast Surg Clin N Am. 2013;21:299–304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Clinique Turin, Groupe Almaviva Santé, Paris, France

    Ahmed S. Zugail, Muaath Alshuaibi & Sébastien Beley

  2. Urology Division, Department of Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia

    Ahmed S. Zugail

  3. Department of Urology, Faculty of Medicine, University of Ha’il, Ha’il, Saudi Arabia

    Muaath Alshuaibi

  4. Sandrine Lombion, EURL Slc, Chamesey, France

    Sandrine Lombion

Authors
  1. Ahmed S. Zugail
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muaath Alshuaibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandrine Lombion
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sébastien Beley
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Research conception and design: AZ, MA, SL and SB. Data acquisition: AZ, MA, and SB. Statistical analysis: AZ, MA, SL and SB. Data analysis and interpretation: AZ, MA, SL and SB. Drafting of the manuscript: AZ, MA, SL and SB. Critical revision of the manuscript: MA and SB. Supervision: SB. Approval of the final manuscript: AZ, MA, SL and SB.

Corresponding author

Correspondence to Ahmed S. Zugail.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

They study was conducted after obtaining approval from the Ethics Committee of Turin Hospital (Approval number: CT2022-74). The study adhered to the Helsinki protocols, and patients provided written, informed consent.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zugail, A.S., Alshuaibi, M., Lombion, S. et al. Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie’s disease in the outpatient setting: a pilot study. Int J Impot Res 36, 140–145 (2024). https://doi.org/10.1038/s41443-023-00744-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-023-00744-y

This article is cited by

Search

Advanced search

Quick links